Thiazoles

Medchemexpress LLC Octanoic acid, 8-bromo-, 1-octylnonyl ester | 2089253-22-3 | MFCD34178802 | 97.0% | 461.56 | C25H49BrO2 | 100 MG

Heptadecan-9-yl 8-bromooctanoate is a brominated lipid ester intended for research use as a building block or modifier in lipid nanoparticle and liposome formulations. As an ester of 8-bromooctanoic acid with a long alkyl alcohol, it combines a hydrophobic tail with a reactive brominated site useful for formulation or synthetic modification.

• Suitable for incorporation into lipid nanoparticles and liposomes.
• Provides a long hydrophobic alkyl chain for membrane integration.
• Contains a brominated functional group for covalent modification.
• Supplied with batch-specific purity to support reproducible results.
• Soluble in common organic solvents for formulation and synthesis workflows.

Medchemexpress LLC Octanoic acid, 8-bromo-, 1-octylnonyl ester | 2089253-22-3 | MFCD34178802 | 97.0% | 461.56 g/mol | C25H49BrO2 | 50 MG

Heptadecan-9-yl 8-bromooctanoate is a brominated lipid ester supplied for research use as a hydrophobic building block for lipid nanoparticles (LNPs) and related lipid formulations. It is used in lipid chemistry and formulation development to introduce a brominated alkyl chain for downstream modification and formulation studies.

• Brominated lipid ester for LNP construction.
• Useful as a hydrophobic building block in lipid formulations.
• Chemical formula C25H49BrO2; molecular weight 461.56 g/mol.
• CAS number 2089253-22-3 for unambiguous identification.
• Purity 97.0% as supplied.
• Storage: pure form -20°C up to 3 years; in solvent -80°C (6 months) or -20°C (1 month).
• Available in multiple pack sizes including solution and solid forms.

Medchemexpress LLC Trans-4-(6,8-dibromo-1,2-dihydroquinazolin-3(4H)-yl)cyclohexanol hydrochloride | 15942-08-2 | MFCD26967902 | 426.57 g/mol | C14H19Br2ClN2O | 10 MG

trans-4-(6,8-dibromo-1,2-dihydroquinazolin-3(4H)-yl)cyclohexanol hydrochloride is a brominated dihydroquinazoline hydrochloride salt documented as an impurity of ambroxol hydrochloride. It is provided for analytical and reference use in pharmaceutical research, principally for impurity identification, characterization, and analytical method development. Consult the supplier's Certificate of Analysis for authoritative purity and storage information.

• Used for impurity profiling and analytical method development.
• Hydrochloride salt form for improved stability and handling.
• Molecular formula C14H19Br2ClN2O; molecular weight 426.57 g/mol.
• Suitable as a reference standard for characterization of related syntheses.
• Certificate of Analysis available for purity and storage specifications.

Apexbio Technology LLC TH-302 918633-87-1 5mg

TH-302 (CAS 918633-87-1) is a hypoxia-activated prodrug comprising a 2-nitroimidazole moiety linked to a brominated isophosphoramide mustard Under severe hypoxic conditions (approximately 0 1% O ) TH-302 undergoes bioreductive activation releasing the cytotoxic alkylating agent Br-IPM selectively within hypoxic tumor microenvironments In vitro studies demonstrate markedly increased cytotoxicity against tumor cell lines under hypoxia with IC50 values ranging from 0 1 to 0 8 M for H460 Caki-1 SK-MEL-5 DU145 and HCT116 cells while IC50 values exceed 40 M in normoxic conditions In H460 xenograft mouse models TH-302 induces dose-dependent tumor growth inhibition without hematological toxicity and increases H2AX-positive cells indicating DNA damage TH-302 is utilized to investigate tumor hypoxia-targeting therapies and mechanisms of selective cytotoxicity

Apexbio Technology LLC TH-302 918633-87-1 10mg

TH-302 (CAS 918633-87-1) is a hypoxia-activated prodrug comprising a 2-nitroimidazole moiety linked to a brominated isophosphoramide mustard Under severe hypoxic conditions (approximately 0 1% O ) TH-302 undergoes bioreductive activation releasing the cytotoxic alkylating agent Br-IPM selectively within hypoxic tumor microenvironments In vitro studies demonstrate markedly increased cytotoxicity against tumor cell lines under hypoxia with IC50 values ranging from 0 1 to 0 8 M for H460 Caki-1 SK-MEL-5 DU145 and HCT116 cells while IC50 values exceed 40 M in normoxic conditions In H460 xenograft mouse models TH-302 induces dose-dependent tumor growth inhibition without hematological toxicity and increases H2AX-positive cells indicating DNA damage TH-302 is utilized to investigate tumor hypoxia-targeting therapies and mechanisms of selective cytotoxicity

Apexbio Technology LLC TH-302 918633-87-1 200mg

TH-302 (CAS 918633-87-1) is a hypoxia-activated prodrug comprising a 2-nitroimidazole moiety linked to a brominated isophosphoramide mustard Under severe hypoxic conditions (approximately 0 1% O ) TH-302 undergoes bioreductive activation releasing the cytotoxic alkylating agent Br-IPM selectively within hypoxic tumor microenvironments In vitro studies demonstrate markedly increased cytotoxicity against tumor cell lines under hypoxia with IC50 values ranging from 0 1 to 0 8 M for H460 Caki-1 SK-MEL-5 DU145 and HCT116 cells while IC50 values exceed 40 M in normoxic conditions In H460 xenograft mouse models TH-302 induces dose-dependent tumor growth inhibition without hematological toxicity and increases H2AX-positive cells indicating DNA damage TH-302 is utilized to investigate tumor hypoxia-targeting therapies and mechanisms of selective cytotoxicity

Apexbio Technology LLC TH-302 918633-87-1 50mg

TH-302 (CAS 918633-87-1) is a hypoxia-activated prodrug comprising a 2-nitroimidazole moiety linked to a brominated isophosphoramide mustard Under severe hypoxic conditions (approximately 0 1% O ) TH-302 undergoes bioreductive activation releasing the cytotoxic alkylating agent Br-IPM selectively within hypoxic tumor microenvironments In vitro studies demonstrate markedly increased cytotoxicity against tumor cell lines under hypoxia with IC50 values ranging from 0 1 to 0 8 M for H460 Caki-1 SK-MEL-5 DU145 and HCT116 cells while IC50 values exceed 40 M in normoxic conditions In H460 xenograft mouse models TH-302 induces dose-dependent tumor growth inhibition without hematological toxicity and increases H2AX-positive cells indicating DNA damage TH-302 is utilized to investigate tumor hypoxia-targeting therapies and mechanisms of selective cytotoxicity